Get the Stockscreener App
22.87
0.40%
0.09
Celldex Therapeutics Inc stock is traded at $22.87, with a volume of 1.14M.
It is up +0.40% in the last 24 hours and up +3.34% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$22.78
Open:
$22.95
24h Volume:
1.14M
Relative Volume:
0.94
Market Cap:
$1.52B
Revenue:
$5.79M
Net Income/Loss:
$-199.61M
P/E Ratio:
-7.598
EPS:
-3.01
Net Cash Flow:
$-188.48M
1W Performance:
+3.58%
1M Performance:
+3.34%
6M Performance:
+8.39%
1Y Performance:
-47.39%
1-Day Range:
$22.59
$23.48
1-Week Range:
$21.77
$23.69
52-Week Range:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
22.87 | 1.51B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Chart based exit strategy for Celldex Therapeutics Inc.July 2025 Trade Ideas & Daily Chart Pattern Signal Reports - Newser
Can Celldex Therapeutics Inc. maintain sales growthTrade Ideas & Consistent Return Investment Signals - خودرو بانک
Can Sage Therapeutics Inc. sustain its profitabilityQuarterly Profit Review & Growth Focused Entry Point Reports - خودرو بانک
Is a relief rally coming for Celldex Therapeutics Inc. holdersDip Buying & Low Drawdown Trading Techniques - Newser
What machine learning models say about Celldex Therapeutics Inc.Weekly Market Report & Low Volatility Stock Recommendations - Newser
Is Celldex Therapeutics Inc. stock entering bullish territoryJuly 2025 Trends & Safe Investment Capital Preservation Plans - Newser
Published on: 2025-09-05 14:01:34 - Newser
How to manage a losing position in Celldex Therapeutics Inc.Weekly Profit Report & Long-Term Safe Return Strategies - Newser
Live market analysis of Celldex Therapeutics Inc.2025 Retail Activity & Stepwise Trade Execution Plans - Newser
Published on: 2025-09-05 06:06:23 - Newser
Will a bounce in Celldex Therapeutics Inc. offer an exitBond Market & Fast Entry and Exit Trade Plans - Newser
How to build a custom watchlist for Celldex Therapeutics Inc.Earnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Analyzing drawdowns of Celldex Therapeutics Inc. with statistical toolsTrade Exit Report & Community Consensus Picks - Newser
Can you recover from losses in Celldex Therapeutics Inc.Portfolio Risk Report & Safe Swing Trade Setup Alerts - Newser
Technical analysis overview for Celldex Therapeutics Inc. stockRecession Risk & Safe Capital Investment Plans - Newser
Can Celldex Therapeutics Inc. outperform in the next rallyForecast Cut & High Yield Stock Recommendations - خودرو بانک
What technical models suggest about Celldex Therapeutics Inc.’s comebackPortfolio Performance Report & Fast Entry High Yield Tips - Newser
What indicators show strength in Celldex Therapeutics Inc.Market Activity Report & Daily Profit Maximizing Trade Tips - Newser
How Celldex Therapeutics Inc. stock performs during market volatility2025 Historical Comparison & Stepwise Trade Signal Implementation - Newser
Is Celldex Therapeutics Inc. trending in predictive chart modelsShare Buyback & Community Consensus Trade Alerts - Newser
Backtesting results for Celldex Therapeutics Inc. trading strategiesMarket Activity Report & Advanced Swing Trade Entry Plans - Newser
Does Celldex Therapeutics Inc. have high return on assetsTrade Entry Report & AI Powered Market Entry Ideas - خودرو بانک
Analyzing recovery setups for Celldex Therapeutics Inc. investorsWeekly Trading Summary & Weekly High Potential Stock Alerts - Newser
Is Celldex Therapeutics Inc. stock poised for growthWeekly Stock Summary & Short-Term Trading Opportunity Alerts - Newser
Target diversity creates opportunity in chronic urticaria - BioCentury
How to read the order book for Celldex Therapeutics Inc.CEO Change & Daily Profit Maximizing Tips - Newser
Custom strategy builders for tracking Celldex Therapeutics Inc.July 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
Is Celldex Therapeutics Inc. gaining market shareJuly 2025 Fed Impact & AI Enhanced Trading Signals - خودرو بانک
will a bounce in celldex therapeutics inc. offer an exitJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
Using economic indicators to assess Celldex Therapeutics Inc. potentialMarket Performance Summary & AI Forecasted Entry and Exit Points - Newser
Should I set a stop loss on Celldex Therapeutics Inc.Volume Spike & Verified Entry Point Signals - خودرو بانک
Is Celldex Therapeutics Inc. impacted by rising ratesMarket Sentiment Report & Comprehensive Market Scan Reports - khodrobank.com
Historical volatility pattern of Celldex Therapeutics Inc. visualizedAnalyst Upgrade & Community Supported Trade Ideas - Newser
Is Celldex Therapeutics Inc. on track to beat earningsQuarterly Performance Summary & Entry and Exit Point Strategies - خودرو بانک
Published on: 2025-09-03 03:10:59 - خودرو بانک
Celldex Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsQuarterly Market Review & Verified Momentum Stock Alerts - beatles.ru
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celldex Therapeutics Inc Stock (CLDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Marucci Anthony S | PRESIDENT & CEO |
Nov 11 '24 |
Buy |
26.82 |
11,500 |
308,430 |
40,284 |
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):